Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Genopole Crete Sept14 2007

582 views

Published on

Published in: Business, Travel
  • Be the first to comment

Genopole Crete Sept14 2007

  1. 1. Crete Meeting on Incubation - 12 September 2007
  2. 2. Where are we ? <ul><li>8 Bioparks </li></ul><ul><li>Over 150 biotech Cies - 4 000 jobs - </li></ul><ul><li>300 public and private research centers </li></ul><ul><li>324 pharma Cies - 32 257 jobs - </li></ul><ul><li>363 medical equipment Cies - 10 434 jobs - </li></ul><ul><li>90% of the French CRO </li></ul><ul><li>The largest European hospital system </li></ul><ul><li>- 41 state-run hospitals ( 25 000 beds) - </li></ul><ul><li>Hot spot for clinical trials </li></ul>30 Km Paris Region Bio-cluster Top 1 in EU for S&T - 7,5 % GDP devoted to R&D -
  3. 3. Genopole Entreprises
  4. 4. <ul><li>CREATE & EXPAND THE INDUSTRIAL BIOPARK </li></ul><ul><li>Increase the number and competitiveness of biotech companies in Evry and the Paris Region by… </li></ul><ul><ul><li>- Creating and incubating new start-up companies </li></ul></ul><ul><ul><li>until market acceptance </li></ul></ul><ul><ul><li>- Attracting existing companies </li></ul></ul><ul><ul><li>- Supporting companies’ development </li></ul></ul>GE : OUR MISSION
  5. 5. 1998 : 4 companies (110 employees) 2006 : 62 companies ( 730 employees ) 160 Million € raised among VC’s 22 products in RPC & clinical trials 25 companies have total sales of 58 M€ GE : OUR ACHIEVEMENTS
  6. 6. 53% Biopharm a: 6% Bioinformatics Informatics 2% Chemistry 9% Others Sequencing – 1,9% Therapeutic screening – 3,7% Drug delivery – 7,4% Diagnostics – 14,8% Therapeutic research – 25,9% From Idea to Market acceptance Cancer Infectious (HIV - HepC) Ophthalmology Metabolics disorders Autoimmune Others PII-b – PII-III Orphan drug GE : GENOPOLE COMPANIES 17% Material Device 13% Agri Biotech Environment
  7. 7. GE : OUR OBJECTIVES 2010 100 companies ( 2 500 employees ) 5 to 10 success stories (IPOs, M&A, Sales) Products on the market Attract Big Pharma companies
  8. 8. <ul><li>An expert committee with academic and industrial members (15) in charge of selecting projects </li></ul><ul><li>G1J - Genopole pre-seed Capital Fund </li></ul><ul><li>Investment / project : 50 000 – 100 000 €, bringing a first entrepreneurial dimension </li></ul><ul><li>A Team of 6 multidisciplinary Project Managers + Network of experts </li></ul>OUR RESOURCES
  9. 9. A Comprehensive set of facilities (80 000 m²) ranging from: - A simple office for the creator (20 to 50 m²) - A specific biotech ‘greenhouse’ (50 to 400 m²) - Larger facilities (500 to 2000+ m² ) OUR RESOURCES
  10. 10. OPERATIONALS FIELDS Crete meeting on Incubation Creation of value Duration Traditional incubation / 24 months From First day to First Round
  11. 11. Duration Interaction with Tech Transfer Office Grants POC/Market Think about « scale-up » Creation of value OPERATIONALS FIELDS
  12. 12. Duration Creation of value - Access to specific skills and expertise : - Business Development - Clinical Development - Regulatory Affairs - Scale-up OPERATIONALS FIELDS
  13. 13. Duration OPERATIONALS FIELDS Creation of value
  14. 14. Finance Science(s) Market Compet. IP Clinique&Reg Scale up 6 4 2 0 Team Bus Dev OPERATIONALS FIELDS

×